Business
Poolbeg identifies novel RSV drug candidates
Poolbeg identifies novel RSV drug candidates.
About this update from Poolbeg Pharma Plc
[{"type":"text","content":"\n \n \n \n Poolbeg Pharma plc\n \n \n \n \n \n \n \n Poolbeg identifies new potential drug candidates for Respiratory Syncytial Virus infections as part of Artificial Intelligence Programme\n \n \n \n \n \n \n \n \n \n Collaboration with OneThree Biotech identifies novel RSV treatments\n \n \n \n \n First time RSV drug candidates identified using AI\n \n \n \n \n Candidates with existing Phase I clinical data packages prioritised to reduce risk\n \n \n \n \n \n \n \n \n Poolbeg Pharma\n \n \n (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a leading infectious disease focused biopharmaceutical company, announces that it has successfully identified potential new drug candidates from its Respiratory Syncytial Virus ('RSV') artificial intelligence ('AI') Programme with\n \n \n OneThree Biotech, Inc.\n \n \n \n \n \n \n \n Since initiating the collaboration in\n \n \n February 2022\n \n \n , Poolbeg's scientific team has worked closely with OneThree to build a tailored AI approach that leverages Poolbeg's unique RSV human challenge trial data in order to identify disease-relevant biological pathways and potential drug targets. Based on those\n \n \n newly discovered drug targets\n \n \n , the collaboration has now identified a number of promising drug candidates to rapidly bring forward to lab-based validation to determine the full potential of these assets.\n \n \n \n \n \n The Company has prioritised compounds with existing Phase I clinical data and which could, if successfully validated, be repositioned as novel treatments for RSV infection. Candidates with solid safety and pharmacodynamic data in humans are well positioned to rapidly enter a clinical trial to generate early human efficacy data for RSV. This is in line with Poolbeg's efficient, capital light clinical development strategy that is at the core of its ambitious growth model. \n \n \n \n \n \n RSV, which inflames the smallest airways of the lungs, usually sends an average of 58,000-80,000 children under the age of 5 to hospital each year in the US alone, according to the US Centers for Disease Control and Prevention (CDC). RSV can also be dangerous for adults over the age of 65, resulting in around 177,000 hospitalisations per year in the United States alone. The current cold and flu season commenced about two months e...